We conducted a multicenter pilot investigation of the safety and feasibility of bone marrow transplantation (BMT) in adults with severe sickle cell disease (SCD) (NCT 01565616) using a reduced toxicity preparative regimen of busulfan (13.2 mg/kg), fludarabine (175 mg/m 2 ) and thymoglobulin (6 mg/kg) and cyclosporine or tacrolimus and methotrexate for graft-vs-host disease (GVHD) prophylaxis. Twenty-two patients (median age 22 years; range 17-36) were enrolled at eight centers. Seventeen patients received marrow from an HLA-identical sibling donor and five patients received marrow from an 8/8 HLA-allele matched unrelated donor.
health-related quality of life were observed. The study satisfied the primary endpoint of 1-year EFS ≥70%. This regimen is being studied in a prospective clinical trial comparing HLA-matched donor BMT with standard of care in adults with severe SCD (NCT02766465).
| INTRODUCTION
Sickle cell disease (SCD) is a hereditary anemia characterized by intermittent pain episodes and progressive damage to vital organs, which contribute to a diminished quality of life and premature mortality. [1] [2] [3] Newborn screening and comprehensive care, pneumococcal prophylaxis, hydroxyurea, transcranial Doppler screening, and chronic red blood cell (RBC) transfusions prevent severe infections, stroke, and other serious complications in childhood and have increased survival to adulthood. Bone marrow transplantation (BMT) from a human leukocyte antigen (HLA)-identical sibling donor is potentially curative, but has been applied quite sparingly and restricted largely to children. [1] [2] [3] Unlike children, young adults with SCD may experience rapid disease progression marked by renal insufficiency, abnormal pulmonary function, and ultimately, pulmonary hypertension, irreversible organ damage, and premature mortality. [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] Chronic pain impairs quality of life, and 40%-60% of adults with SCD are unemployed. 14 Supportive care for adult patients ameliorates symptoms, but does not address the overwhelming and progressive nature of this disease. Refinements in conditioning regimens, improved post-BMT supportive care, and better donor selection have increased the safety of allogeneic BMT for SCD, but early transplant-related mortality remains a risk.
If safety and efficacy of BMT can be established, it may become a suitable, if not preferred, therapeutic option for adults with severe SCD.
A less toxic regimen was sufficient for donor engraftment after HLA-ID sibling BMT in adults with severe SCD, but this regimen can be extended to alternate donor BMT. 15, 16 This is an important consideration because only 18% of persons with SCD in the USA will have an HLA-identical sibling donor and only 19% will have an HLA-identical unrelated donor (URD). [17] [18] [19] A pre-BMT conditioning regimen consisting of busulfan (Bu), fludarabine (Flu), and anti-thymocyte globulin has been tested in patients with thalassemia and with chronic granulomatous disease. [20] [21] [22] [23] The elimination of cyclophosphamide (Cy) reduces the risk of venocclusive disease and in comparison, of Bu-Cy regimens, Bu-Flu regimens has been demonstrated to be associated with associated with better overall, event free and non-relapse free survival. 20, 21 The lack of studies comparing BMT to standard of care in SCD remains a major gap in evidence. 4, 24 As a part of planning for a multicenter clinical trial comparing HCT to standard of care we conducted a pilot investigation to determine the safety and feasibility of BMT with this conditioning regimen in adults with severe SCD (NCT 01565616). We now report on the safety and efficacy of this approach in young adults with severe SCD.
| METHODS

| Patients
The clinical trial protocol was approved by the Institutional Review [25] [26] [27] Eligible subjects had adequate physical function and organ function Umbilical cord blood or peripheral blood stem cell donors were excluded.
Patients were offered alternative treatment options such as hydroxyurea or automated RBC exchange transfusion. The hemoglobin S level was decreased to and maintained ≤30% by transfusion within 7 days of commencing transplant conditioning and chelation and hydroxyurea were discontinued 48 hours before conditioning. Patients with cirrhosis of the liver, uncontrolled bacterial, viral or fungal infection, seropositive for HIV, had received a previous BMT, were currently receiving an investigational drug or device or off-label use of a drug or device, had demonstrated lack of compliance with prior medical care were unwilling to use approved contraception for at least 6 months after transplant, had a history of substance abuse that interfered with their care, or were pregnant or breast feeding were excluded from the study.
| Treatment
Based on the experience that the substitution of Flu for Cy in the myeloablative conditioning regimen improve safety and retain efficacy after HLA-matched sibling or URD BMT for leukemia 20 or thalassemia, 28 we elected to test a reduced toxicity conditioning regimen of Bu: 3.2 mg/kg administered as a single daily dose IV on days −8 through −5 and dosing.
Based upon Bu population pharmacokinetics (PK) of once-daily IV Bu described by Madden et al, 29 we targeted Bu PK to ensure a uniform dose exposure to achieve a steady state of 600-900 ng/mL (target were also employed. Strategies to preserve fertility preservation were offered according to institutional practice.
| Study design
The primary endpoint was 1-year event-free survival (EFS). EFS was defined as survival with stable donor erythropoiesis with no new clinical evidence of SCD. Primary or late graft rejection, disease recurrence, and death were defined as events for this endpoint. Pre-specified secondary endpoints were overall survival (OS), hematopoietic recovery as evi- 
| Lineage specific chimerism analysis
To measure erythroid-lineage chimerism, pyrosequencing of the sickle cell mutation was used to quantify the relative levels of normal and sickle beta-globin mRNA in patient blood samples as previously described.
31-33
Peripheral blood samples were sorted on post-transplant days 28, 100, and 180 days by multidimensional FACS into CD3+CD56-(T-lymphocytes) and CD45+ side scatter mid-hi (granulocytes). Genomic DNA extracted from peripheral blood and peripheral blood CD3+CD56-(T-lymphocytes) was analyzed for a variable number of tandem repeats (VNTRs) to detect donor engraftment in mononuclear cells and CD3+
lymphocytes. 33 Percent donor chimerism was analyzed by PCR-based VNTR analysis and quantified by routine phosphorimager analysis.
| Statistical analysis
The primary goal of this multicenter phase II study was to determine the feasibility of achieving >70% rate of survival with donor erythropoiesis at 1-year post transplant using a conditioning regimen with Bu/Flu/ATG in adult patients with severe SCD. The original target sample size of this pilot study was 15 patients with the goal of demonstrating that 11 or more patients would survive 1 year with donor hematopoiesis (EFS 73%). Due to high demand for enrollment on the study, this was revised, with the permission of the DSMB, to 20 patients. The DSMB subsequently gave permission to further expand enrollment to 22 patients in order to gain further experience with URDs.
EFS and OS were calculated using the method of Kaplan and
Meier. The cumulative incidence of acute GVHD and chronic GVHD was calculated from the time of transplant to the time of each event with death as a competing risk using the cmprsk package in R version 3.5.1. Changes in continuous measures between two time points were assessed using a paired t test. HRQOL measurement was based on the PROMIS-57. Raw scores for each domain were transformed to a standardized T-score using the PROMIS assessment manual (version 1.0). The depression, anxiety, physical function, pain interference, and fatigue domains were normed to a score of 50, SD 10, based on the average for the US populations. 34 Ability to participate in social roles and activities and sleep disturbance were normed to a population enriched with patients with chronic disease. A higher PROMIS T-score represents more of the concept being measured. Pain intensity was collected as a raw score on a 0-10 scale. PROMIS 57 domains were analyzed using a two-sided paired t test; P-values were adjusted for multiplicity of testing by a modified Holm approach in which the primary endpoint of changes between baseline and one-year post-transplant was tested at the 0.05 level. Changes between baseline and 6 months, and between 6 months and 1 year, were each tested at the nominal 0.0125 level to provide significance at the 0.05 level after adjustment.
3 | RESULTS
| Subject characteristics
The trial enrolled 22 patients between July 2012 and June 2015. The median age was 22.5 (range 17-36) years; 36% of patients were male.
Patient characteristics are summarized in Table 1 . Subjects were enrolled in the study only if eligibility was confirmed by ERC review.
Indications endorsed by the ERC for study enrollment were stroke (2), recurrent ACS (2), recurrent pain events (15), chronic transfusions 3.2 | Event-free survival, overall survival, and engraftment
For the entire cohort, the 1-year EFS was 86% (95% CI, 63%-95%)
and OS was 91% (95% CI, 68%-98%), which satisfied the pre-specified primary endpoint threshold of EFS ≥70% ( Figure 1A ; Table 2 ). All Autopsy revealed bilateral diffuse alveolar damage and bronchiolitis obliterans. There was also an incidental finding of post-transplant lymphoproliferative foci in the lung associated with EBV reactivation.
All survivors, at 1-year post-BMT, were alive at the last date of contact at a median of 2.7 years post-BMT (range, 2.2-5.0 years). All patients had stable donor chimerism at year 1 (Table 3) For patients who underwent BMT from matched siblings, the one-year OS was 94% (95% CI, 65%-99%) 1-year EFS 94% (95% CI,
65%-99%) and 3-year EFS 88% (95% CI, 61%-97%). Among five
patients who had an 8/8 HLA allele-matched URD transplant, one patient developed grade III acute GVHD and one patient died due to severe, chronic GVHD, one patient had secondary graft failure followed by a successful second URD BMT, and three patients survive event-free. Four of five URD recipients survive disease-free. One-year OS 80% (95% CI, 20%-97%) EFS 60% (95% CI, 13%-88%).
| Graft-vs-host disease
Four of 22 patients developed acute GVHD and the day 180 cumulative incidence was 18% (95% CI, 5-37) ( Tables S1   and S2 ). Both domains were significantly compromised at baseline. No other changes were statistically significant. Pain intensity was highly variable over time within patients; no significant changes were observed in this measure.
| Donor chimerism after BMT
As mixed chimerism is frequently observed after BMT for SCD, the percentage of donor cells was measured at 28, 100, 180, and 365 days after BMT (Table 2) . Full donor myeloid chimerism was observed at all time points. Initially, mixed donor chimerism in the lymphoid compartment was observed in 21 of 22 patients. The T-cell donor chimerism increased over time with a mean of 82% at day +365. The delay in full donor T-cell engraftment was not associated with graft rejection or GVHD. 
| Other SCD-related measurements
| Other BMT toxicities
There were eight episodes of bacteremia (Table 3 ). There were no instances of invasive fungal infection. CMV reactivation, without active CMV disease, occurred in 10 patients. EBV viremia was detected in three patients, and EBV-related post-transplant lymphoproliferative disease was observed in one patient who died of GVHD.
No patient developed sinusoidal obstruction syndrome. One patient with PRES died of an intracranial hemorrhage and the patient with pulmonary failure and bronchiolitis obliterans also had severe interstitial fibrosis noted on autopsy.
| DISCUSSION
We report the results of the first NIH-supported, multicenter BMT trial for and young adult patients with SCD. The reduced toxicity myeloablative regimen of Bu, Flu, and ATG was sufficient for primary engraftment in all but one case and did not cause significant toxicity in this group of young adults. We exceeded a target of achieving a 1-year endpoint of ≥70% EFS that we had reasoned would be necessary before pursuing a comparative clinical trial of the regimen. These results are comparable to the 81% OS and EFS in patients >16 years of age after HLA identical sibling BMT for SCD as reported in a recent international survey 35 and 87% EFS after HLA-identical sibling in adult SCD recipients BMT reported in a single center by Hsieh et al. 16 The EFS probability we observed also is similar to results in children with SCD treated by HLA-identical sibling BMT. 35 These outcomes, if reproduced in a larger trial, may be considered acceptable to support broader adoption of allo-BMT for adult patients with severe SCD compared with the risk of premature mortality in adults with SCD.
Despite these promising results, there is a prevailing view that a reduced intensity conditioning regimen in lieu of myeloablation would Secondary bone marrow aplasia 2 (9) 1 (6) 1 (20) be more suitable in this patient population. 36 This is supported in part by a perception that efficacy and safety are optimized after reduced intensity conditioning, particularly in patients with significant vasoocclusive end-organ co-morbidities. However, this view is challenged by the favorable toxicity profile we observed and the low incidence of graft rejection. An important barrier to a successful transplant outcome in SCD is graft rejection, which can be mitigated by the intensity of the regimen. Several reports of reduced intensity or minimal toxicity regimens suggest these are not sufficiently intensive for sustained donor engraftment, particularly after HLA-mismatched or URD HCT, 30, [37] [38] [39] or engraftment is extended only by the administration of long-term immunosuppressive therapy in many patients. 16, 40 In addition, in an analysis of 95 patients with SCD who received related or URD HCT between 2002 and 2013, all 13 graft rejection events occurred in patients who received reduced intensity conditioning.
There were no rejections in patients who received myeloablative conditioning. 41 Thus, we conclude that this pilot investigation warrants further investigation in adults with severe SCD. While it would also be useful to compare the reduced intensity and myeloablative regimens in SCD directly, sample size requirements might constrain the feasibility of a comparison trial.
This study completed enrollment in 28 months compared to 6-9 years for full accrual in previous multicenter studies of BMT for SCD. 1, 30 This, in part, reflects the increasing interest in BMT as a curative therapy for adults with SCD in the sickle cell community, which is based upon excellent reports described in pediatric and adult patients. 1, 16, 40, 42 The pattern of early mixed lymphoid chimerism, which improved over time in this study, is similar to our previous observations. 31, 32, 43 Most patients had mixed donor chimerism in the lymphoid compartment that probably reflects the effect of rabbit ATG on donor T-cell engraftment. The donor lymphoid chimerism increased over time.
Mixed lymphoid chimerism did not appear to predict graft rejection or protect from GVHD. Notably, there was full donor erythroid chimerism at nearly all post-transplant time points, indicating a survival advantage of donor erythroid precursors.
We observed a fatal episode of PRES in a single patient who was receiving a combination of a calcineurin inhibitor and corticosteroid, which underscores the well-known risk of PRES in patients with SCD. 30, 44 The sudden onset of PRES, with no preceding hypertension or prodromal manifestations, also suggests that PRES may not be avoidable even when preventive measures are employed. The rate of PRES observed in this study was substantially lower than observed in the recent pediatric URD BMT trial in SCD. Another limitation of this pilot study is that we did not capture biomarkers of hemolysis or details of healthcare utilization related to SCD post-BMT. We observed a significant improvement in physical functioning and a significant decrease in pain interference domains, at 1-year post-BMT, while changes in fatigue, anxiety, depression, sleep disturbance, satisfaction with participation in social roles, and pain intensity domains did not change significantly. We note that, at study entry, physical functioning and pain interference were the domains of HRQoL in which the subjects were significantly more compromised than the reference population.
Pain intensity in this study was ascertained using a single question on PROMIS-57 measure. This question is limited to pain intensity in the previous 7 days, and is subject to recall bias. A limitation of this study is that it did not capture detailed patient reported outcomes of residual pain burden among survivors of BMT for SCD. The use of an electronic pain diary has the potential to capture patient-reported dimensions of pain in real-time and is not subject to recall bias. Such studies are more able to determine the trajectory of chronic pain as well as the course of its resolution following BMT. Insights gained 
